Home Articoli
Dichiarazione di trasparenza per gli articoli di ricerca

Editoriale

Dichiarazione di trasparenza per gli articoli di ricerca
Douglas G Altman, David Moher

Evidence 2013;5(8): e1000054 doi: 10.4470/E1000054

Pubblicato: 29 agosto 2013

Copyright: © 2013 Altman. Questo è un articolo open-access, distribuito con licenza Creative Commons Attribution, che ne consente l’utilizzo, la distribuzione e la riproduzione su qualsiasi supporto esclusivamente per fini non commerciali, a condizione di riportare sempre autore e citazione originale.

1. PLoS Medicine Editors. An unbiased scientific record should be everyone’s agenda. PLoS Med 2009;6:e1000038.
2. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
3. Gibson LM, Brazzelli M, Thomas BM, Sandercock PA. A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full. Trials 2010;11:43.
4. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med 2012;9:e1001189.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
6. Vitry AI. Reporting of studies on new medicines in major medical journals: a case study in breast cancer. Clin Pharmacol Ther 2010;87:398-400.
7. Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev 2011:MR000031.
8. Nankervis H, Baibergenova A, Williams HC, Thomas KS. Prospective registration and outcome-reporting bias in randomized controlled trials of eczema treatments: a systematic review. J Invest Dermatol 2012;132:2727-34.
9. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302:977-84.
10. Rosenthal R, Dwan K. Comparison of randomized controlled trial registry entries and content of reports in surgery journals. Ann Surg 2013;257:1007-15.
11. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:1-193.
12. Dwan K, Kirkham JJ, Williamson PR, Gamble C. Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open 2013;3.
13. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64.
14. Ochodo EA, de Haan MC, Reitsma JB, Hooft L, Bossuyt PM, Leeflang MM. Overinterpretation and misreporting of diagnostic accuracy studies: evidence of “spin.” Radiology 2013;267:581-8.
15. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-5.
16. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ 2008;336:1472-4.
17. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol 2000;53:973-9.
18. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 2013;24:1238-44.
19. Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216:46-55.
20. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomized trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723.
21. Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst 2012;104:982-9.
22. Bagul NB, Kirkham JJ. The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clin Exp Hypertens 2012;34:548-54.
23. Shukralla AA, Tudur-Smith C, Powell GA, Williamson PR, Marson AG. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res 2011;97:20-9.
24. Knol MJ, Egger M, Scott P, Geerlings MI, Vandenbroucke JP. When one depends on the other: reporting of interaction in case-control and cohort studies. Epidemiology 2009;20:161-6.
25. Lee W, Bindman J, Ford T, Glozier N, Moran P, Stewart R, et al. Bias in psychiatric case-control studies: literature survey. Br J Psychiatry 2007;190:204-9.
26. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009;4:e7960.
27. Zintzaras E, Papathanasiou A, Ziogas D, Voulgarelis M. The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskelet Disord 2012;13:113.
28. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007;99:236-43.
29. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 2009;4:e7824.
30. Dirnagl U, Macleod MR. Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice. Br J Pharmacol 2009;157:1154-6.
31. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
32. Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum 2012;64:2059-67.
33. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.